Pharmacology, Toxicology and Pharmaceutical Science
Afatinib
19%
Biodistribution
23%
Biological Marker
22%
Breast Cancer
7%
Cachexia
7%
Carcinogenesis
24%
Chelating Agent
7%
Chemotherapy
8%
Chimeric Antibody
6%
Clinical Trial
10%
Disease
19%
Divalent
8%
Epidermal Growth Factor Receptor
29%
Epitope
9%
Glioblastoma
13%
Head and Neck Squamous Cell Carcinoma
13%
Immunosuppressive Agent
10%
Immunotherapy
13%
Inflammation
15%
Iodine-131
9%
Liver Metastasis
10%
Lung Cancer
13%
Lutetium 177
13%
Malignant Neoplasm
100%
Metastasis
10%
microRNA
10%
Monoclonal Antibody
18%
Monoclonal Antibody CC49
13%
Mouse
25%
Mouse Model
23%
Mucin
50%
Mucin 1
8%
Mucin 4
59%
Neoplasm
85%
Ovary Cancer
22%
Ovary Carcinoma
8%
Pancreas Adenocarcinoma
58%
Pancreas Cancer
89%
Pancreas Tumor
13%
Pharmacokinetics
36%
Radioactive Iodine
13%
Radioisotope
16%
Single Chain Fragment Variable Antibody
19%
Small Cell Lung Cancer
7%
Solid Malignant Neoplasm
19%
Temozolomide
7%
Therapy Resistance
8%
Tumor Antigen
8%
Tumor Microenvironment
20%
Uvomorulin
7%
Medicine and Dentistry
Afatinib
13%
Biological Marker
21%
CA-125
8%
Cancer
12%
Cancer Cell
14%
Cancer Growth
9%
Cancer Therapy
10%
Carboxy Terminal Sequence
8%
Cell Line
12%
Cell Migration
8%
Clinical Trial
11%
Cystic Pancreatic Lesion
13%
Desmoplasia
8%
Diagnosis
19%
Disease
26%
Early Diagnosis
10%
Epidermal Growth Factor Receptor
20%
Exosome
23%
Fibroblast
12%
Geranyltransferase
9%
Head and Neck Squamous Cell Carcinoma
13%
Immune Checkpoint Blockade
8%
Immunosuppressive Drug
9%
Immunosuppressive Treatment
7%
Immunotherapy
13%
Krukenberg Tumor
8%
Liver Metastasis
10%
Lung Cancer
7%
Malignant Neoplasm
52%
Metastatic Carcinoma
32%
Mucin
41%
Mucin 1
9%
Mucin 4
49%
Mucin 5AC
9%
Neoplasm
57%
Neutrophil Gelatinase Associated Lipocalin
13%
Ovarian Cancer
15%
Overall Survival
7%
Pancreas Adenocarcinoma
75%
Pancreas Cancer
96%
Pancreatic Ductal Adenocarcinoma
7%
Radiation Therapy
8%
Radiosensitivity
16%
Radiosensitization
8%
Small Cell Lung Cancer
14%
Surface Enhanced Raman Spectroscopy
13%
Targeted Therapy
8%
Therapy Resistance
7%
Tumor Antigen
11%
Upregulation
10%
Keyphrases
Antibody Labeling
6%
Benign Disease
6%
Biosensing Technology
6%
Cancer Antigen
6%
Cancer Marker
6%
Cancer Resistance
9%
Cancer Therapy
6%
Cancer-related
7%
Carbohydrate Antigen 19-9 (CA19-9)
11%
Chronic Pancreatitis
7%
Clinical Potential
6%
Desmoplasia
6%
Early Diagnosis
9%
Endothelin Axis
6%
Gold Nanoprobes
6%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
6%
Immune Regulation
6%
Liver Metastasis
7%
Macrophage Inhibitory cytokine-1 (MIC-1)
13%
Malignancy
6%
Metastasis
16%
Model Potential
6%
MUC16
32%
MUC4
28%
MUC4 mucin
13%
Mucin
16%
Ovarian Cancer
8%
Pancreas
7%
Pancreatic Adenocarcinoma
7%
Pancreatic Cancer
32%
Pancreatic Cancer Biomarkers
6%
Pancreatic Cancer Treatment
15%
Pancreatic Ductal Adenocarcinoma
32%
Pancreatic Tumor
7%
Pathological Function
6%
Pre-metastatic Niche Formation
6%
Radiohalogens
9%
Radioiodine
6%
Radiometals
6%
Recombinant
7%
Serum miRNAs
6%
Specific Monoclonal Antibodies
7%
Stromal Heterogeneity
7%
Targeting Cancer Stem Cells
6%
Therapeutic Target
8%
Triple-negative Breast Cancer Cells
6%
Tumor
7%
Tumor Microenvironment Factors
6%
Tumorigenesis
13%
Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL)
19%